<DOC>
	<DOCNO>NCT02143960</DOCNO>
	<brief_summary>The purpose study compare clinical performance VelaShape III device CoolSculpt reduction waist , love handle flank .</brief_summary>
	<brief_title>VelaShape III Device Comparison Cryolipolysis Circumferential Reduction</brief_title>
	<detailed_description>VelaShape non-invasive ( break skin ) device Body Reshaping Cellulite Treatment . VelaShape combine control infrared ( IR ) light conduct bipolar radiofrequency ( RF ) energies mechanical manipulation . The CoolSculpt System noninvasive device reduces fat freeze fat cell break apart .</detailed_description>
	<criteria>1 . Informed consent process complete subject complete consent . 2 . Fitzpatrick Skin Type I VI 3 . Having excess fat deposit bilaterally waist / love‐handle / flank area . 4 . BMI score great 18.5 less 29.9 ‐ normal overweight , obese . 5 . Willing follow treatment follow‐up schedule post‐treatment care instruction . 6 . Willingness refrain change diet/ exercise/medication regimen entire course study . 7 . If female , pregnant , lactate must either post‐menopausal , surgically sterilize , use medically acceptable form birth control least 3 month prior enrollment ( i.e. , oral contraceptive , contraceptive implant , barrier method spermicide abstinence ) . 8 . Willing photograph image take treated area use de‐identified evaluation , publication presentation . 1 . Subjects history excessive weight fluctuation expect gain/lose 5 pound ) study time frame . 2 . Pregnant plan become pregnant , give birth le 3 month ago , and/or breast feeding . 3 . Having active electrical implant anywhere body , pacemaker internal defibrillator . 4 . Having permanent implant treat area , metal plate inject chemical substance silicone . 5 . Known photosensitivity . 6 . Having receive treatment laser , RF device treat area within 6 month treatment study . 7 . Having undergone surgery treat area within 12 month treatment study , include liposuction . 8 . Having undergoing form treatment active cancer , history skin cancer cancer area treat , include presence malignant pre‐malignant pigment lesion . 9 . Suffering significant concurrent illness , cardiac disorder , diabetes ( type I II ) , lupus , porphyria , pertinent neurological disorder . 10 . Having know anticoagulative thromboembolic condition take anticoagulation medication one week prior treatment course ( allow inclusion , temporary cessation use per subject 's physician discretion ) . 11 . History immunosuppression/immune deficiency disorder ( include HIV infection AIDS ) currently use immunosuppressive medication . 12 . Suffering hormonal imbalance may affect weight per Investigator 's discretion . 13 . History significant lymphatic drainage problem impaired circulation area treat . 14 . Suffering significant skin condition treat area inflammatory skin condition , include , limited , open laceration abrasion active cold sore herpes sore prior treatment ( duration resolution per Investigator 's discretion ) treatment course . 15 . History keloid scarring , abnormal wound heal / prone bruising . 16 . History epidermal dermal disorder ( particularly involve collagen microvascularity ) . 17 . Use isotretinoin ( Accutane® ) within 6 month treatment study . 18 . Allergy component lotion ( VelaSpray Ease ) use study . 19 . Cryoglobulinemia , Paroxysmal cold hemoglobinuria , know sensitivity cold cold urticaria Raynaud 's disease . 20 . Neuropathic disorder post‐herpetic neuralgia diabetic neuropathy , impaired skin sensation area treat . 21 . Hernia area treat . 22 . Participation study another device drug within 9 month prior enrollment study , treat area involve . 23 . As per Investigator 's discretion , physical mental condition might make unsafe subject participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Syneron</keyword>
	<keyword>Velashape</keyword>
	<keyword>ELOS</keyword>
	<keyword>Zeltiq</keyword>
	<keyword>Cryolipolysis</keyword>
</DOC>